在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human α-galactosidase,αGAL ELISA Kit

  • 中文名稱(chēng):
    人α半乳糖苷酶(αGAL)酶聯(lián)免疫試劑盒
  • 貨號(hào):
    CSB-E09457h
  • 規(guī)格:
    96T/48T
  • 價(jià)格:
    ¥3600/¥2500
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品描述:
    人α半乳糖苷酶(αGAL)酶聯(lián)免疫試劑盒(CSB-E09457h)為雙抗夾心法ELISA試劑盒,定量檢測(cè)血清、血漿、組織勻漿樣本中的GLA含量。GLA即α-半乳糖苷酶A,相關(guān)背景上,其缺陷會(huì)引發(fā)法布里病。在研究機(jī)制方面,主要探索補(bǔ)充該酶的治療方式,通過(guò)提供外源性GLA改善機(jī)體代謝,減輕因底物蓄積造成的多器官損害,為法布里病治療帶來(lái)希望。試劑盒檢測(cè)范圍為7.8 pg/mL-500 pg/mL,該產(chǎn)品適用于法布雷病機(jī)制研究、溶酶體貯積癥模型構(gòu)建、藥物干預(yù)效果評(píng)價(jià)等科研領(lǐng)域本品僅用于科研,不用于臨床診斷,產(chǎn)品具體參數(shù)及操作步驟詳見(jiàn)產(chǎn)品說(shuō)明書(shū)。
  • 別名:
    AGAL_HUMAN ELISA Kit; Agalsidase alfa ELISA Kit; Alpha D galactosidase A ELISA Kit; Alpha D galactoside galactohydrolase 1 ELISA Kit; Alpha D galactoside galactohydrolase ELISA Kit; Alpha gal A ELISA Kit; Alpha galactosidase A ELISA Kit; Alpha-D-galactosidase A ELISA Kit; Alpha-D-galactoside galactohydrolase ELISA Kit; Alpha-galactosidase A ELISA Kit; GALA ELISA Kit; Galactosidase; alpha ELISA Kit; GLA ELISA Kit; GLA protein ELISA Kit; Melibiase ELISA Kit
  • 縮寫(xiě):
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類(lèi)型:
    serum, plasma, tissue homogenates
  • 檢測(cè)范圍:
    7.8 pg/mL-500 pg/mL
  • 靈敏度:
    1.95 pg/mL
  • 反應(yīng)時(shí)間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測(cè)波長(zhǎng):
    450 nm
  • 研究領(lǐng)域:
    Cardiovascular
  • 測(cè)定原理:
    quantitative
  • 測(cè)定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線(xiàn)性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of human αGAL in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
     SampleSerum(n=4)
    1:100Average %86
    Range %81-92
    1:200Average %92
    Range %87-96
    1:400Average %84
    Range %81-86
    1:800Average %102
    Range %100-106
  • 回收率:
    The recovery of human αGAL spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9490-98
    EDTA plasma (n=4)8884-93
  • 標(biāo)準(zhǔn)曲線(xiàn):
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    5002.420 2.451 2.436 2.272
    2502.065 2.107 2.086 1.922
    1251.663 1.705 1.684 1.520
    62.51.165 1.183 1.174 1.010
    31.20.735 0.788 0.762 0.598
    15.60.482 0.499 0.491 0.327
    7.80.328 0.341 0.335 0.171
    00.162 0.166 0.164  
  • 數(shù)據(jù)處理:
  • 貨期:
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能:
    Catalyzes the hydrolysis of glycosphingolipids and participates in their degradation in the lysosome.
  • 基因功能參考文獻(xiàn):
    1. GLA variants found included R118C (n = 2), D83N, and D313Y (n = 7); IVS6-22 C>T, IVS4-16 A>G, IVS2+990C>A, 5'UTR-10 C>T (n = 4), IVS1-581 C>T, IVS1-1238 G>A, 5'UTR-30 G>A, IVS2+590C>T, IVS0-12 G>A, IVS4+68A>G, IVS0-10 C>T, IVS2-81-77delCAGCC, IVS2-77delC. We found that patients with common heart disease did not contain a substantial number of patients with undiagnosed Fabry disease. PMID: 29227985
    2. GLA DNA screening protocols starting from the dialysis population and upstream extended to families of affected individuals may be an effective strategy to maximize the early identification of subjects with Fabry disease. PMID: 30099469
    3. family study with the classical phenotype of Fabry disease due to the novel nonsense mutation c.607G>T (p.E203X) of the GLA gene; the Fabry disease phenotype is highly variable in heterozygote females, even within the same family PMID: 28152533
    4. It negatively regulates calcification of human aortic valve interstitial cells. PMID: 29653899
    5. Results from a study on gene variability markers in early-stage human embryos shows that GLA is a putative variability marker for the 3-day, 8-cell embryo stage. PMID: 26288249
    6. Presence of isolated heterozygous -10C >T SNP is not associated with clinically relevant symptoms or organ manifestations as seen in Fabry disease. PMID: 29794742
    7. The D313Y variant in the GLA gene was not Fabry disease causative in 2 Danish families. PMID: 29037082
    8. The mutation p.D313Y in the GLA gene may lead to organ manifestations and elevation of the Fabry-specific biomarker lyso-globotriaosylsphingosine. PMID: 28276057
    9. Four novel GLA pathogenic mutations are reported and evidence of pathogenicity of the D313Y mutation is provided. PMID: 28988177
    10. alpha-Galactosidase A genotype N215S does not lead to the development of a classical Fabry phenotype but induces a specific cardiac variant of Fabry disease mimicking nonobstructive hypertrophic cardiomyopathy. PMID: 29018006
    11. GLA c.196G>C variant is a genetic risk factor for cerebral small-vessel occlusion and non-cardioembolism in Japanese males but not in females. PMID: 28275245
    12. we presented the clinical characters of a Chinese FD pedigree mimicking familial episodic pain. Furthermore, our finding suggests that a novel double mutation of GLA (c.273_276del TGAT in cis with c.281G>T) is associated with FD PMID: 27531472
    13. Results showed that most Fabry disease patients carrying GLA IVS4+919A did not show abnormal cardiac phenotypes. The near-absence of GLA IVS4+919A in heart disease cohort suggested that this variant is not a frequent cause of overt heart diseases in Taiwan. PMID: 28377241
    14. This longitudinal Fabry Registry study analyzed data from patients with Fabry disease to determine the incidence and type of severe clinical events following initiation of enzyme replacement therapy (ERT) with agalsidase beta, as well as risk factors associated with occurrence of these events PMID: 27510433
    15. alpha-galactosidase A mutation, IVS4-type Fabry disease has features similar to those of classic Fabry disease and a higher frequency of deep white matter hyperintensities and a higher incidence of infarctions and pulvinar signs than in healthy controls PMID: 26869469
    16. We demonstrate that the wild-type sequence harbors an hnRNP A1 and hnRNP A2/B1-binding exonic splicing silencer (ESS) overlapping the 5'splice site (5'ss) that prevents pseudoexon inclusion.we demonstrate that splice switching oligonucleotide (SSO) mediated blocking of the pseudoexon 3'ss and 5'ss effectively restores normal GLA splicing PMID: 27595546
    17. Four patients had non-amenable mutant forms of a-Gal based on the validated cell-based assay conducted after treatment initiation and were excluded from primary efficacy analyses only. PMID: 27834756
    18. Mesenchymal stem cells with reduced GLA activity are prone to apoptosis and senescence due to impaired autophagy and DNA repair capacity. PMID: 28098348
    19. we review the various types of GLA variants and recommend that pathogenicity be considered only when associated with elevated globotriaosylceramide in disease-relevant organs and tissues as analyzed by mass spectrometry. PMID: 27195818
    20. findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future PMID: 28430823
    21. Results found a novel heterozygous stop codon mutation in exon 1 of the GLA gene in female patients with Fabry Disease with methylation in the non-mutated allele thought to be associated with the clinical severity of the disease. PMID: 28087245
    22. Study described the demographic data, wide clinical spectrum of phenotypes, and GLA mutation spectrum of Fabry disease in Korea. Most of the patients had classical Fabry disease, with a 4 times higher incidence than that of late-onset Fabry disease, indicating an underdiagnosis of mild, late-onset Fabry disease. PMID: 28723748
    23. we reviewed other small molecules that were reported to have a stabilizing effect on some GLA missense mutations in vitro and might be developed to act in synergy or as an alternative to 1-deoxygalactonojirimycin PMID: 27916943
    24. No pathogenic mutations in the coding regions of the GLA gene were identified in this group of patients and thus no Fabry disease was found in this study. PMID: 26981927
    25. High desphospho-uncarboxylated matrix Gla protein level, reflecting a poor vitamin K status, seems to be associated with kidney damage and may be also a marker of cardiovascular risk in CKD patients PMID: 27100101
    26. Similar central nervous system manifestations in patients with the IVS4 mutation or classical Fabry mutations. PMID: 28166746
    27. Case Report: Kidney transplantation from a mother with unrecognized Fabry disease to her son with low alpha-galactosidase A activity. PMID: 26971403
    28. p.M187R GLA mutation in Fabry disease causes a severe systemic and ophthalmologic phenotype, in both male and female patients. PMID: 28225726
    29. The results of the current study suggest that the GLA haplotype D313Y does not lead to severe organ manifestations as seen in genotypes known to be causal for classical Fabry disease. PMID: 27059467
    30. We report a case of Fabry disease with a p.R301X (c.901 C>T) mutation in a 39-year-old man who was being treated for chronic sclerosing glomerulonephritis for 2 years. Family screening tests showed that the proband's mother, sister, and daughter had the same mutation with different phenotypes. PMID: 27156739
    31. Case Report: hypertrophic obstructive cardiomyopathy with Fabry disease with the GLA E66Q mutation. PMID: 27160240
    32. We conclude that a mild GLA variant is typically characterized by high residual enzyme activity and normal biomarker levels. We found evidence that these variants can still be classified as a distinctive, but milder, sub-type of FD. PMID: 26415523
    33. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for alpha-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy. PMID: 26564084
    34. Study describes 5 novel mutations found in the GLA gene of patients with clinical diagnosis of Fabry disease. PMID: 26691501
    35. The present study confirms the heterogeneity of mutations in Fabry disease and the importance of molecular analysis for genetic counseling, female heterozygotes detection as well as therapeutic decisions. PMID: 26297554
    36. GLA gene variations correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma PMID: 26070511
    37. results directly implicated the GLA mutation p.E66Q as the genetic etiology of the Chinese renal variant FD pedigree. PMID: 26456105
    38. This study indicated that the p.E66Q variant of GLA does not affect the progression of chronic kidney disease. PMID: 24718812
    39. Thus, inheritance of the CIH caused an mRNA deregulation altering the GLA expression pattern, producing a tissue glycolipid storage. PMID: 26334996
    40. data strongly suggest that the GLA p.(Arg118Cys) variant does not segregate with Fabry disease clinical phenotypes in a Mendelian fashion, but might be a modulator of the multifactorial risk of cerebrovascular disease PMID: 25468652
    41. In Fabry disease patients, the alpha-galactosidase A-10T allele appears to be causal for neurological manifestations. PMID: 25423912
    42. Some clinical cases of some members of a Sicilian family to express phenotypical variability of Anderson-Fabry disease in subjects with the same genetic mutation in alpha galactosidase A gene, are reported. PMID: 25281798
    43. Case Report: immunohistologically detected synaptopodin upregulation in foamy podocytes in Fabry disease due to novel alpha-galactosidase A mutation. PMID: 25295576
    44. These data confirmed that the specific approach can effectively contribute to the identification of pathological mutations in GLA. PMID: 25382311
    45. The novel mutation p.M187R/g7219 T>G is associated with a particularly malignant cardiac phenotype in males and females over 40 years. PMID: 24679964
    46. OC follows a gene duplication strategy while MGP variability was obtained mostly by the use of multiple promoters and alternative splicing, leading to proteins with additional functional characteristics and alternative gene regulatory pathways. [review] PMID: 25068814
    47. It is clear that a certain intronic haplotype in males with cryptogenic stroke is associated with reduced GLA expression and function. PMID: 25101867
    48. GLA p.E66Q mutation is a genetic risk factor for cerebral small-vessel occlusion in elderly Japanese PMID: 23724928
    49. residues important for expression of the GLA activity PMID: 24386359
    50. A Fabry disease patient and his daughter had the mutation c.493 G > C in the 3d exon of the GLA gene. D165H substitution affects protein folding. This highly conserved AA may be a key amino acid for enzyme functionality. PMID: 24398019

    顯示更多

    收起更多

  • 相關(guān)疾病:
    Fabry disease (FD)
  • 亞細(xì)胞定位:
    Lysosome.
  • 蛋白家族:
    Glycosyl hydrolase 27 family
  • 數(shù)據(jù)庫(kù)鏈接:

    HGNC: 4296

    OMIM: 300644

    KEGG: hsa:2717

    STRING: 9606.ENSP00000218516

    UniGene: Hs.69089



主站蜘蛛池模板: 国产精品理论片| 一本无码中文字幕在线观| 亚洲精品久久久久中文字幕一福利| 狂野欧美激情性xxxx按摩| 性开放的欧美大片| 国产美女牲交视频| 国产精品人妻一区夜夜爱| 日日躁夜夜躁狠狠躁| 少妇人妻上班偷人精品视频| 亚洲欧美成人久久一区| 俺去俺来也www色官网| 精品国产亚洲一区二区三区在线观看| 久久久国产打桩机| 中文在线а√在线| 亚洲另类成人小说综合网| 乱子伦av无码中文字| 色八区人妻在线视频免费| 在线观看人成视频免费| 亚洲精品456在线播放| 四虎影视国产精品久久| 亚洲成色综合网站在线| 成在人线av无码免费看网站直播| 国产成人啪精品午夜网站a片免费| 人妻夜夜添夜夜无码av | 亚洲精品一区二区三区不卡| 日韩乱码人妻无码系列中文字幕| 人妻熟女av一区二区三区 | 天天躁日日躁狠狠躁一区| 西西人体做爰大胆gogo| 98色婷婷在线| 国产系列丝袜熟女精品网站| 免费的污污的网站在线观看| 自拍偷自拍亚洲精品被多人伦好爽 | 边喂奶边中出的人妻| 久久国产精品久久精品国产| 亚洲中文字幕久久无码| 国产喷水1区2区3区咪咪爱av| 亚洲色欲色欲天天天www| 久久久综合九色合综| 激情久久av一区av二区av三区| 怡红院免费的全部视频|